Safety & Tolerability Study of Chimeric Antigen Receptor T-Reg Cell Therapy in Living Donor Renal Transplant Recipients
| 対象疾患 | Kidney Transplant Rejection, End Stage Renal Disease |
|---|---|
| 相 | 第1/2相 |
| スポンサー | Sangamo Therapeutics |
| ステータス | 完了 |
| 参加者数 | 26 名 |
| 介入（薬剤） | TX200-TR101 |
| 開始日 | 2021年3月17日 |
| 完了日 | 2024年7月11日 |
| 結果公開日 | 2026年7月2日 |
概要
The purpose of this study is to evaluate the safety and tolerability of TX200-TR101 and its effects on the donated kidney in living donor kidney transplant recipients. TX200-TR101 is a product made from a kidney transplant recipient's own immune cells, which are genetically modified and designed to help the transplant recipient's body accept their donated kidney and prevent their immune system from rejecting it.
Short Term Safety and Tolerability of TX200-TR101 Infusion.
| Treatment With TX200-TR101 (DL1) | 1 Participants |
|---|---|
| Treatment With TX200-TR101 (DL2) | 0 Participants |
| Treatment With TX200-TR101 (DL3) | 0 Participants |
| Treatment With TX200-TR101 (DL4) | 1 Participants |
| Controls | 2 Participants |
| Donors | 0 Participants |
BENITIONS で見る ClinicalTrials.gov の原文を見る
同じ疾患の他の治験
- Study to Evaluate the Safety and Efficacy of GSK1278863 in Recombinant Human Erythropoieti — GlaxoSmithKline
- Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using th — Boston Children's Hospital
- Bone in CKD Alkali Response (BICARb Pilot Trial) — Albert Einstein College of Medicine
- Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients — The University of Texas at Arlington
- Efficacy, Safety and Tolerability of VS-01 in Adult Patients With Acute-on-Chronic Liver F — Genfit
- High-protein Oral Supplement With Liposomal Curcumin in Adults Undergoing Hemodialysis. — University of Florida